Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack

Circulation

Volumn 125, Issue 23, 2012, Pages 2914-2921

  James, Stefan K ^a   Storey, Robert F ^b   Khurmi, Nardev S ^c   Husted, Steen ^d   Keltai, Matyas ^e   Mahaffey, Kenneth W ^f   Maya, Juan ^c   Morais, Joao ^g   Lopes, Renato D ^f   Nicolau, Jose C ^h   Pais, Prem ⁱ   Raev, Dimitar ^j   Lopez Sendon, Jose L ^k   Stevens, Susanna R ^f   Becker, Richard C ^f  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g Cardiology Division Santo Andrés Hospital   (Portugal)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^j Ministry of Interior   (Bulgaria)

^k UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

more..

Author keywords

acute coronary syndrome; antiplatelet drugs; cardiovascular diseases; stroke; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DEATH; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; BRAIN ISCHEMIA; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; STROKE; TICLOPIDINE;

EID: 84862146372     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.082727     Document Type: Review

References (16)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1716 and N Engl J Med. 2001;345: 1506]. N Engl J Med. 2001;345:494-502.
2. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
3. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121: 1188-1199.
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
5. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599-605.
6. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006-3016.
7. Jensen JK, Medina H, Norgaard BL, Ovrehus KA, Jensen JM, Nielsen LH, Maurovich-Horvat P, Engel LC, Januzzi JL, Hoffmann U, Truong QA. Association of ischemic stroke to coronary artery disease using computed tomography coronary angiography. Int J Cardiol. Published online before print May 4, 2011. doi:10.1016/j.ijcard.2011.04.006. http://dx.doi.org/10.1016/j.ijcard.2011.04. 006. Accessed May 11, 2012.
8. Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, Budaj A, Avezum A, Allegrone J, FitzGerald G, Steg PG; GRACE Investigators. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100:1-6.
9. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-STsegment-elevation myocardial infarction: the Crusade (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation. 2009;119:1873-1882.
10. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988.
11. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364: 331-337.
12. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
13. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA 2°P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J. 2009;158:335-341.e3.
14. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20-33.
15. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708.
16. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.